Effects of baseline symptom burden on treatment response in COPD.

ABSTRACT:

Rationale

In symptomatic patients with COPD, the decision whether to initiate maintenance treatment with a single agent or a combination of long-acting bronchodilators remains unclear.

Objective

To investigate whether baseline symptomatic status influences response to tiotropium/olodaterol treatment.

Materials and methods

Post hoc analysis of the randomized OTEMTO^® studies (NCT01964352; NCT02006732), in which patients with moderate-to-severe COPD received placebo, tiotropium 5 µg, tiotropium/olodaterol 2.5/5 µg, or tiotropium/olodaterol 5/5 µg once daily for 12 weeks via the Respimat^® inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany). Impact of baseline symptomatic status (modified Medical Research Council [mMRC] score) on response to t

SUBMITTER: Martinez FJ 

PROVIDER: S-EPMC6324615 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature